Twice-daily radiation therapy cuts deaths from head and neck cancer
Treating head and neck cancer patients with a twice-daily radiation therapy combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress 2017...
View ArticleWomen treated for precursor of breast cancer can expect to live as long as...
Women over 50 who have been treated for ductal carcinoma in situ (DCIS) are more likely to be alive ten years later than women in the general population, according to new research presented at the...
View ArticleEuropean cancer patients call for more access to innovation in oncology
At the European Cancer Congress 2017 in Amsterdam, the European Cancer Patient Coalition launched a new white paper on the Value of Innovation in Oncology. It makes recommendations for sustainable and...
View ArticleSocial media at medical congresses
The American Society of Hematology (ASH) Annual Congress dedicated a special-interest session on social media in 2016, called ‘Social Media and Clinical Trials: Physicians, Pharma and Patients‘. The...
View ArticleWhen radiation therapy causes heart disease
It has been known for almost a century that thoracic radiotherapy can cause damage to the heart.[2] However, the first study suggesting that this damage may play an important role in patient outcomes...
View ArticleESMO 2017
Are you ready for ESMO 2017? The Video Journal of Oncology is excited to be attending the ESMO 2017 Congress in Madrid, Spain this September! We have an excellent line-up of interviews scheduled with...
View ArticleFDA Approves Bevacizumab Biosimilar
Bevacizumab-bvzr (Zirabev; Pfizer), a biosimilar to bevacizumab (Avastin; Genentech) has been given the go-ahead by the FDA for five indications. Bevacizumab-bvzr will be used for the treatment of...
View ArticleAll.Can: a world-first survey into cancer care inefficiencies
Completed by a total of 3,981 cancer patients across 10 countries, All.Can is the biggest survey of its kind aiming to highlight and improve patient-reported inefficiencies in cancer care. During an...
View ArticleWorld first in bladder cancer with FDA approval of erdafitinib
Following the release of trial data, the FDA has approved erdafitinib for the treatment of adult patients with fibroblast growth factor receptor 3 (FGFR3) altered metastatic urothelial cancer that has...
View ArticleNHS approval for ovarian cancer drug, olaparib
Olaparib, a maintenance therapy for ovarian cancer, may prolong the benefit of initial treatment in BRCA1/2 mutated ovarian cancer patients who had a complete or partial clinical response after...
View ArticleFurther positive data published for lung cancer screening
The early detection of lung cancer is an exciting field with the potential to greatly improve patient survival. The topic of screening dominates the agenda in this area. Highly anticipated data from...
View ArticleKiller T-cell discovery at Cardiff
Cellular therapies are an exciting area in cancer research and clinical trials. The most widely known, CAR T-cell therapy, has had two product approvals in the hematological oncology space. CAR-T...
View ArticleDarolutamide gets the OK in Europe for nmCRPC
Metastatic castration-resistant prostate cancer (mCRPC) has limited treatment options and metastatic growth is associated with increased comorbidities. To put the size of this group into context,...
View ArticlePositive TAPUR data in advanced CRC presented at GI Cancer Symposium
The 2020 Gastrointestinal (GI) Cancers Symposium presented the latest data in the field, including findings from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. TAPUR, the first...
View ArticleFDA accepts subcutaneous combination of pertuzumab and trastuzumab for HER2+...
Breast cancer is the most common type of malignancy in women.1 Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of breast cancers worldwide and is of great...
View ArticleCAR T-cell therapy guided by scorpion toxin for glioblastoma
The first chimeric antigen receptor T-cell (CAR T-cell) therapy using chlorotoxin (CLTX), a toxin found in the venom of scorpions, demonstrated antitumor activity in a preclinical study recently...
View ArticleNICE response to COVID-19 infection – delivery of systemic anticancer treatments
In light of the ongoing COVID-19 pandemic, the National Institute for Health and Care Excellence (NICE) have put together a rapid guideline on the delivery of systemic anticancer treatments.1 The...
View ArticleUse of pembrolizumab in patients with PS2 NSCLC
Clinical trials assessing the efficacy of pembrolizumab have previously enrolled patients with performance status (PS) 0–1. However, almost a fifth of patients with non-small cell lung cancer (NSCLC)...
View ArticleERAS protocols for breast cancer patients: safe and feasible outpatient...
The Enhanced Recovery After Surgery (ERAS) approach was initially pioneered for colorectal surgery by a group of surgeons in northern Europe, and the principles have since spread across the world and...
View ArticleMulti-cancer detection and localization for more than 50 cancer types
The early detection of cancer improves outcomes for patients – in terms of both reducing treatment burden and improving the chances of a cure. Screening programs are used for many common cancer types...
View Article